
|Articles|August 22, 2014
ACS Exec Exits After Projecting $40-Million Revenue Slump
Advertisement
Last summer the
The society stated in a press release at that time that adding MacMaster to the "seminal post" was "... part of a transformative effort designed to save even more lives from cancer."
Less than 18 months later that executive is gone, and the ACS is facing a projected $40-million revenue loss linked to an especially poor showing from its hallmark
events.
Source: MedPage Today
Read the full story:
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
2
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5




